Biopol Chemicals Limited Reports Strong Financial Performance for FY26
Biopol Chemicals Limited reported exceptional financial performance for FY26 with revenue from operations growing 64.87% to ₹8,114.33 lakhs and net profit surging 108.12% to ₹897.41 lakhs. The Board approved these audited results on April 30, 2026, with statutory auditors providing an unmodified opinion. The company's balance sheet strengthened significantly with total assets reaching ₹6,977.53 lakhs.
*this image is generated using AI for illustrative purposes only.
Biopol Chemicals Limited has delivered impressive financial performance for the year ended March 31, 2026, with the Board of Directors approving the audited results at their meeting held on April 30, 2026. The company's statutory auditors, M/s. M B Jajodia & Associates, Chartered Accountants, have issued an unmodified opinion on the financial results.
Financial Performance Highlights
The company demonstrated strong operational performance across key financial metrics for FY26:
| Financial Metric | FY26 (₹ Lakhs) | FY25 (₹ Lakhs) | Growth (%) |
|---|---|---|---|
| Revenue from Operations | 8,114.33 | 4,922.13 | +64.87% |
| Total Income | 8,137.16 | 4,922.13 | +65.34% |
| Net Profit | 897.41 | 431.23 | +108.12% |
| Profit Before Tax | 1,205.84 | 578.04 | +108.58% |
The company's revenue from operations increased substantially to ₹8,114.33 lakhs in FY26 from ₹4,922.13 lakhs in the previous year, marking a growth of 64.87%. Total income for the year reached ₹8,137.16 lakhs, including other income of ₹22.83 lakhs.
Profitability Analysis
Biopol Chemicals showcased strong profitability improvements during FY26. The company's profit before tax more than doubled to ₹1,205.84 lakhs from ₹578.04 lakhs in FY25, representing a growth of 108.58%. After accounting for tax expenses of ₹308.43 lakhs, the net profit for the period stood at ₹897.41 lakhs, compared to ₹431.23 lakhs in the previous year.
Half-Year Performance
The second half of FY26 showed particularly strong performance:
| Parameter | H2 FY26 (₹ Lakhs) | H2 FY25 (₹ Lakhs) | Growth (%) |
|---|---|---|---|
| Revenue from Operations | 4,948.60 | 3,384.68 | +46.22% |
| Net Profit | 603.98 | 300.09 | +101.24% |
Balance Sheet Strength
The company's balance sheet reflects significant expansion and strengthening of its financial position as of March 31, 2026:
| Balance Sheet Item | FY26 (₹ Lakhs) | FY25 (₹ Lakhs) |
|---|---|---|
| Total Assets | 6,977.53 | 3,167.64 |
| Shareholders' Funds | 4,992.09 | 1,358.89 |
| Property, Plant & Equipment | 1,423.84 | 25.45 |
| Trade Receivables | 2,778.69 | 1,665.64 |
Earnings Per Share and Corporate Actions
The company reported earnings per share of ₹10.83 for FY26, compared to ₹5.45 in the previous year. The paid-up share capital increased to ₹1,080.54 lakhs from ₹791.10 lakhs, reflecting the company's capital expansion activities during the year.
Regulatory Compliance
Biopol Chemicals confirmed that it does not fall under the category of 'Large Corporate' as per SEBI circular requirements for the financial year ended March 31, 2026. The company operates as a single business segment and is listed on the SME platform of NSE, making it exempt from IND-AS applicability. The financial results are available on both the NSE website and the company's official website at biopolchemicals.com.
Historical Stock Returns for Biopol Chemicals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.99% | +2.68% | +26.84% | +10.85% | +10.85% | +10.85% |
What factors drove Biopol Chemicals' exceptional 65% revenue growth, and are these growth drivers sustainable in FY27?
How will the significant expansion in property, plant & equipment from ₹25.45 lakhs to ₹1,423.84 lakhs impact the company's production capacity and future margins?
Given the doubling of trade receivables to ₹2,778.69 lakhs, what strategies will management implement to optimize working capital management?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
